UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: AMAG S&P 600 Component |
| Industry | Pharmaceutical Industry |
| Founded | November 9, 1981 (1981-11-09) |
| Headquarters | United States |
| Products | Pharmaceutics |
| Website | www |
| Footnotes / references Founded |
|
AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company is a publicly traded company listed on NASDAQ under the symbol "AMAG".
In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
AMAG Pharmaceuticals Inc. operates in the researching, marketing as well as distribution of its drugs. The areas that the company markets its products include the United States, Canada and the European Union.
AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of US$71,500,000 in 2013.
In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020.
In June 2015 the company acquired Cord Blood Registry for $700 million.
In 2014 AMAG acquired Lumara Health, formerly KV Pharmaceutical Company.
In 2015, the company's revenue reached $418 million. AMAG had 552 employees.
The company's research and tests focus on iron deficiency anemia and related intravenous drugs.
In June 2009, the company's main product Ferumoxytol, an oral medication used on adult patients with chronic kidney disease, was approved by US Food and Drug Administration.
In December 2011, Health Canada approved Ferumoxytol, under the brand name Feraheme, for use in treating both dialysis and non-dialysis dependent chronic kidney disease patients, as well as for treatment of adult patients suffering from iron deficiency anemia.
From 2010 to 2014, AMAG had a distribution agreement with Takeda which granted them exclusivity to the Canadian and European Union markets, where the drug is sold under the brand names Feraheme and Rienso, respectively.
| 2016-06-08 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-02 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-05-09 | Lower Price Target | Deutsche Bank | Hold | $42.00 to $35.00 |
| 2016-05-09 | Lower Price Target | Deutsche Bank AG | Hold | $42.00 to $35.00 |
| 2016-05-05 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $37.00 |
| 2016-05-04 | Lower Price Target | Leerink Swann | Outperform | $45.00 to $40.00 |
| 2016-05-04 | Downgrade | Raymond James | Outperform to Market Perform | |
| 2016-05-04 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-05-04 | Downgrade | Raymond James Financial Inc. | Outperform to Market Perform | |
| 2016-04-16 | Reiterated Rating | Leerink Swann | Outperform | |
| 2016-03-28 | Lower Price Target | Robert W. Baird | Outperform | $26.00 to $25.00 |
| 2016-03-28 | Lower Price Target | Leerink Swann | Outperform | $25.00 to $23.00 |
| 2016-03-28 | Downgrade | Ladenburg Thalmann | Buy to Neutral | |
| 2016-03-28 | Upgrade | Jefferies Group | Underperform to Hold | $16.00 to $19.00 |
| 2016-02-18 | Lower Price Target | Guggenheim | Buy | $54.00 to $51.00 |
| 2016-01-28 | Initiated Coverage | Northland Securities | Outperform | $40.00 |
| 2016-01-21 | Initiated Coverage | Barclays | Equal Weight | $32.00 |
| 2016-01-21 | Initiated Coverage | Barclays PLC | Equal Weight | $32.00 |
| 2016-01-14 | Lower Price Target | Deutsche Bank | Hold | $43.00 to $42.00 |
| 2016-01-03 | Reiterated Rating | Jefferies Group | Buy | |
| 2015-12-28 | Reiterated Rating | Jefferies Group | Buy | $70.00 |
| 2015-12-10 | Reiterated Rating | Leerink Swann | Outperform | $71.00 to $45.00 |
| 2015-11-19 | Lower Price Target | Deutsche Bank | Hold | $50.00 to $43.00 |
| 2015-11-12 | Reiterated Rating | Jefferies Group | Buy | $28.95 to $70.00 |
| 2015-11-04 | Lower Price Target | Deutsche Bank | Hold | $58.00 to $50.00 |
| 2015-11-04 | Lower Price Target | Jefferies Group | Buy | $80.00 to $70.00 |
| 2015-11-02 | Boost Price Target | Robert W. Baird | Outperform | $54.00 to $55.00 |
| 2015-09-23 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-09-18 | Reiterated Rating | Jefferies Group | Buy | $80.00 |
| 2015-09-11 | Reiterated Rating | Leerink Swann | Buy | $85.00 |
| 2015-09-03 | Initiated Coverage | Deutsche Bank | Hold | $75.00 to $71.00 |
| 2015-08-31 | Initiated Coverage | Raymond James | Outperform | $75.00 |
| 2015-08-27 | Boost Price Target | Guggenheim | Buy | $85.00 to $89.00 |
| 2015-08-18 | Initiated Coverage | Jefferies Group | Buy | $80.00 |
| 2015-06-25 | Reiterated Rating | Deutsche Bank | Hold | $75.00 |
| 2015-06-12 | Initiated Coverage | Deutsche Bank | Hold | $75.00 |
| 2015-06-08 | Initiated Coverage | Guggenheim | Buy | $85.00 |
| 2015-05-18 | Boost Price Target | Leerink Swann | Outperform | $60.00 to $85.00 |
| 2015-05-06 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $41.00 to $51.00 |
| 2015-05-06 | Boost Price Target | Leerink Swann | Outperform | $54.00 to $60.00 |
| 2015-03-09 | Initiated Coverage | Cowen and Company | Outperform | |
| 2015-02-11 | Set Price Target | Jefferies Group | Buy | $55.00 |
| 2015-01-26 | Reiterated Rating | FBR & Co. | Market Perform | $42.00 |
| 2015-01-26 | Reiterated Rating | FBR & Co | Market Perform | $42.00 |
| 2015-01-16 | Boost Price Target | Jefferies Group | Buy | $40.00 to $55.00 |
| 2015-01-12 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $39.00 to $41.00 |
| 2014-12-02 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $22.00 to $39.00 |
| 2014-09-30 | Upgrade | Jefferies Group | Hold to Buy | $21.00 to $40.00 |
| 2014-09-30 | Upgrade | FBR & Co. | Market Perform to Outperform | $21.00 to $36.00 |
| 2014-08-13 | Initiated Coverage | FBR & Co. | Market Perform | $21.00 |
| 2014-01-23 | Lower Price Target | Summer Street | Buy | $30.00 |
| 2014-01-23 | Upgrade | Jefferies Group | Underperform to Hold | $16.00 to $19.00 |
| 2014-01-22 | Downgrade | Ladenburg Thalmann | Buy to Neutral | |
| 2013-10-24 | Reiterated Rating | Summer Street | Buy | $31.00 to $43.00 |
| 2013-10-18 | Upgrade | Robert W. Baird | Neutral to Outperform | $25.00 to $26.00 |
| 2013-09-30 | Lower Price Target | Ladenburg Thalmann | Buy | $27.00 to $25.00 |
| 2013-06-10 | Reiterated | Ladenburg Thalmann | Buy | $25 to $23 |
| 2012-07-26 | Reiterated | Ladenburg Thalmann | Buy | $15 to $17.50 |
| 2012-05-17 | Upgrade | Ladenburg Thalmann | Neutral to Buy | $15 |
| 2012-05-10 | Downgrade | Robert W. Baird | Outperform to Neutral | $21 to $17 |
| 2012-05-10 | Downgrade | Ladenburg Thalmann | Buy to Neutral | |
| 2011-10-24 | Upgrade | Ladenburg Thalmann | Neutral to Buy | $18 to $18 |
| 2011-06-30 | Reiterated | Ladenburg Thalmann | Neutral | $18.50 to $20 |
| 2010-10-29 | Reiterated | Ladenburg Thalmann | Neutral | $24 to $15.50 |
| 2010-10-29 | Downgrade | Canaccord Genuity | Buy to Hold | $52 to $19 |
| 2010-09-21 | Reiterated | Ladenburg Thalmann | Neutral | $38.50 to $24 |
| 2010-07-29 | Downgrade | Robert W. Baird | Outperform to Neutral | $40 to $36 |
| 2010-01-12 | Upgrade | Citigroup | Hold to Buy | |
| 2009-12-17 | Reiterated | Robert W. Baird | Outperform | $60 to $55 |
| 2009-10-05 | Downgrade | Jefferies & Co | Buy to Hold | $60 to $44 |
| 2009-09-10 | Downgrade | Citigroup | Buy to Hold | |
| 2009-09-01 | Reiterated | Ladenburg Thalmann | Buy | $69 to $60 |
| 2009-07-01 | Reiterated | Jefferies & Co | Buy | $55 to $60 |
| 2016-06-08 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-02 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-05-09 | Lower Price Target | Deutsche Bank | Hold | $42.00 to $35.00 |
| 2016-05-09 | Lower Price Target | Deutsche Bank AG | Hold | $42.00 to $35.00 |
| 2016-05-05 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $37.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AMAG 24 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Fund Advisors | 3.44M |
| BlackRock Institutional Trust Company, N.A. | 0.94M |
| JANUS CAPITAL MANAGEMENT LLC | 0.80M |
| TEACHERS ADVISORS INC | 0.44M |
| Apex Capital Management | 0.30M |
| Numeric Investors LLC | 0.27M |
| RUSSELL FRANK CO/ | 0.22M |
| BlackRock Investment Management, LLC | 0.19M |
| TIAA CREF INVESTMENT MANAGEMENT LLC | 0.17M |
| Breithorn Capital Management | 0.14M |
| MANAGED ACCOUNT ADVISORS LLC | 0.14M |
| EverPoint Asset Management, LLC | 0.12M |
| ALYDAR PARTNERS LLC | 95000 |
| Piermont Capital Management LLC | 89910 |
| BlackRock Group LTD | 65082 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| ADAGE CAPITAL PARTNERS GP LLC | 11.60% (2546592) | ADXS / AMAG / BDBD / CALA / FPRX / HTWR / IGOI / PBYI / PSUN / PTGX / |
| HEIDEN WILLIAM K President & CEO | 1.61% (353015) | AMAG / ATRA / |
| THOMAS FRANK E CFO, COO, Interim CEO | 0.63% (138195) | AMAG / |
| Grund Nicholas Chief Commercial Officer | 0.30% (66324) | AMAG / |
| Caffe Steven SVP, Ch. Dev. and Reg. Officer | 0.27% (59400) | AMAG / |
| Bolgiano Elizabeth Scott Chief Human Resources Officer | 0.26% (56918) | AMAG / |
| Townsend Scott B SVP, General Counsel | 0.26% (56851) | AMAG / |
| Holmes Scott A Chief Accounting Officer | 0.24% (53304) | AMAG / KERX / |
| Myles Edward H Chief Financial Officer | 0.24% (53294) | AMAG / |
| Vittiglio Joseph SVP, General Counsel | 0.24% (52854) | AMAG / AVEO / |
| Krop Julie SVP Clinical & Regulatory, CMO | 0.24% (51636) | AMAG / |
| Edward P. Jordan SVP, Sales and Marketing | 0.18% (39213) | AMAG / |
| Butcher James Alan EVP, Chief Business Officer | 0.13% (28418) | AMAG / |
| White Christopher G Chief Business Officer and SVP | 0.13% (28400) | AMAG / |
| NARACHI MICHAEL | 0.11% (23900) | AMAG / CLDN / OREX / |
| Wilson Kenneth H SVP, Sales and Marketing | 0.11% (23387) | AMAG / |
| SCOON DAVEY | 0.10% (21935) | AMAG / BIOD / OFIX / |
| Russell Lesley | 0.10% (21335) | AMAG / ECYT / ENTA / TLOG / |
| SANTINI GINO | 0.09% (19510) | AMAG / HZNP / ICPT / VTAE / |
| Madison Greg EVP, Chief Commercial Officer | 0.09% (18800) | AMAG / KERX / |
| Crouse Geoffrey EVP | 0.09% (18750) | AMAG / |
| PEREZ ROBERT J | 0.08% (17535) | AMAG / CBST / |
| Fallon John A. | 0.07% (15399) | AMAG / EXAS / PODD / |
| DE SILVA RAJIV | 0.07% (14822) | AMAG / ENDP / |
| Deptula Barbara | 0.07% (14660) | AMAG / |
| SULAT JAMES R | 0.06% (13127) | AMAG / MNTA / |
| KELLEY BRIAN P | 0.03% (5571) | AMAG / APRN / GMCR / |
| ALLEN LEE F MD PhD Chief Medical Officer and EVP | 0.01% (2229) | AMAG / ARGS / SPPI / |
UM